{"name":"Cinnagen","slug":"cinnagen","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"CinnaPoietin®","genericName":"CinnaPoietin®","slug":"cinnapoietin","indication":"Anemia associated with chronic kidney disease","status":"phase_3"},{"name":"Aflibercept (Regeneron, USA)","genericName":"Aflibercept (Regeneron, USA)","slug":"aflibercept-regeneron-usa","indication":"Metastatic colorectal cancer (in combination with chemotherapy)","status":"phase_3"},{"name":"Cetuximab + FOLFIRI","genericName":"Cetuximab + FOLFIRI","slug":"cetuximab-folfiri","indication":"Metastatic colorectal cancer, KRAS wild-type","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"cardiovascular","drugs":[{"name":"Interferon Beta-1A Prefilled Syringe","genericName":"Interferon Beta-1A Prefilled Syringe","slug":"interferon-beta-1a-prefilled-syringe","indication":"Relapsing-remitting multiple sclerosis","status":"phase_3"},{"name":"Ocrelizumab (CinnaGen, Iran)","genericName":"Ocrelizumab (CinnaGen, Iran)","slug":"ocrelizumab-cinnagen-iran","indication":"Relapsing forms of multiple sclerosis","status":"phase_3"},{"name":"Pegylated interferon beta-1a","genericName":"Pegylated interferon beta-1a","slug":"pegylated-interferon-beta-1a","indication":"Relapsing forms of multiple sclerosis","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"CinnaTropin®","genericName":"CinnaTropin®","slug":"cinnatropin","indication":"Growth hormone deficiency in children","status":"phase_3"},{"name":"Nephrovit","genericName":"Nephrovit","slug":"nephrovit","indication":"Other","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"Nordilet®","genericName":"Nordilet®","slug":"nordilet","indication":"Type 2 diabetes","status":"phase_3"},{"name":"Sulfonylurea/non-sulfonylurea insulin secretagogues","genericName":"Sulfonylurea/non-sulfonylurea insulin secretagogues","slug":"sulfonylurea-non-sulfonylurea-insulin-secretagogues","indication":"Type 2 diabetes","status":"phase_3"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"infectious","drugs":[{"name":"Omalizumab (CinnaGen)","genericName":"Omalizumab (CinnaGen)","slug":"omalizumab-cinnagen","indication":"Moderate to severe allergic asthma","status":"phase_3"}]}],"pipeline":[{"name":"CinnaPoietin®","genericName":"CinnaPoietin®","slug":"cinnapoietin","phase":"phase_3","mechanism":"CinnaPoietin is an erythropoiesis-stimulating agent that mimics erythropoietin to stimulate red blood cell production.","indications":["Anemia associated with chronic kidney disease","Chemotherapy-induced anemia","Anemia in patients with cancer"],"catalyst":""},{"name":"CinnaTropin®","genericName":"CinnaTropin®","slug":"cinnatropin","phase":"phase_3","mechanism":"CinnaTropin® is a recombinant human growth hormone that binds to growth hormone receptors to promote growth, metabolism, and body composition changes.","indications":["Growth hormone deficiency in children","Growth hormone deficiency in adults","Short stature in children"],"catalyst":""},{"name":"Aflibercept (Regeneron, USA)","genericName":"Aflibercept (Regeneron, USA)","slug":"aflibercept-regeneron-usa","phase":"phase_3","mechanism":"Aflibercept is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), inhibiting angiogenesis and vascular permeability.","indications":["Metastatic colorectal cancer (in combination with chemotherapy)","Wet age-related macular degeneration","Diabetic macular edema","Retinal vein occlusion"],"catalyst":""},{"name":"Cetuximab + FOLFIRI","genericName":"Cetuximab + FOLFIRI","slug":"cetuximab-folfiri","phase":"phase_3","mechanism":"Cetuximab blocks EGFR signaling while FOLFIRI chemotherapy damages DNA, together targeting colorectal cancer cells through dual mechanisms.","indications":["Metastatic colorectal cancer, KRAS wild-type","Recurrent or metastatic colorectal cancer as first-line or later-line therapy"],"catalyst":""},{"name":"Interferon Beta-1A Prefilled Syringe","genericName":"Interferon Beta-1A Prefilled Syringe","slug":"interferon-beta-1a-prefilled-syringe","phase":"phase_3","mechanism":"Interferon Beta-1A binds to type I interferon receptors on cell surfaces to activate antiviral and immunomodulatory pathways.","indications":["Relapsing-remitting multiple sclerosis","Secondary progressive multiple sclerosis"],"catalyst":""},{"name":"Nephrovit","genericName":"Nephrovit","slug":"nephrovit","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Nordilet®","genericName":"Nordilet®","slug":"nordilet","phase":"phase_3","mechanism":"Nordilet is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which increases the levels of incretin hormones to enhance glucose-dependent insulin secretion.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"Ocrelizumab (CinnaGen, Iran)","genericName":"Ocrelizumab (CinnaGen, Iran)","slug":"ocrelizumab-cinnagen-iran","phase":"phase_3","mechanism":"Ocrelizumab is a monoclonal antibody that targets and depletes CD20-positive B cells.","indications":["Relapsing forms of multiple sclerosis","Primary progressive multiple sclerosis"],"catalyst":""},{"name":"Omalizumab (CinnaGen)","genericName":"Omalizumab (CinnaGen)","slug":"omalizumab-cinnagen","phase":"phase_3","mechanism":"Omalizumab is a monoclonal antibody that binds to circulating immunoglobulin E (IgE), preventing its interaction with high-affinity IgE receptors on mast cells and basophils.","indications":["Moderate to severe allergic asthma","Chronic idiopathic urticaria","Nasal polyposis"],"catalyst":""},{"name":"Pegylated interferon beta-1a","genericName":"Pegylated interferon beta-1a","slug":"pegylated-interferon-beta-1a","phase":"phase_3","mechanism":"Pegylated interferon beta-1a works by stimulating the body's immune system to fight multiple sclerosis.","indications":["Relapsing forms of multiple sclerosis"],"catalyst":""},{"name":"Sulfonylurea/non-sulfonylurea insulin secretagogues","genericName":"Sulfonylurea/non-sulfonylurea insulin secretagogues","slug":"sulfonylurea-non-sulfonylurea-insulin-secretagogues","phase":"phase_3","mechanism":"Sulfonylurea/non-sulfonylurea insulin secretagogues stimulate insulin release from pancreatic beta cells.","indications":["Type 2 diabetes"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPVEZlS2tORUhoa2VrX0lJZC13d0xueDc2R2xxZ1U2WFRVT1g3TEpoSXFpYVBCdW9WbFhrdFo5V0VNMS1uY0h6dXRMNkU5RmtHR2dOT29MMGtfSDdzaml3ZEJfSE4zTTF0NUdzMlBHMW8wcGh4dlFxZU5MUzNxelBmUVNjcXNoQm5MZkJUUjJHRmpleDVBQng1Z2pCTm5PVTlnWHNUVjkyOFVnV0U4MU1WNjMyOG8?oc=5","date":"2026-03-02","type":"regulatory","source":"The Pharma Letter","summary":"EMA clears CinnaGen biosimilar to Lilly’s Forsteo - The Pharma Letter","headline":"EMA clears CinnaGen biosimilar to Lilly’s Forsteo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOTWloTDdMRzdweklsakRGSnpNVWowM3g1aGhpc3B5YUNfSEp2ek1wZEVhb2xsaUNzcDdMWjViOVFWM29Cb1RvTHd1NE5NS3lIRS1iVUpGRktUdnZhX1ZZTXlSci15cTI2OUhWTjN6a3VyVVk2S2xGRHpGN1Ixck9lODEtbnhtUnpDaWdlX3BuY2xJY0ZrSmNqeWdBYTJPWHJ4MXpINWtIN015dnRpajBSb1l0aGhYdw?oc=5","date":"2023-11-28","type":"trial","source":"Generics and Biosimilars Initiative","summary":"Phase III trial results of CinnaGen’s ocrelizumab similar biotherapeutic product - Generics and Biosimilars Initiative","headline":"Phase III trial results of CinnaGen’s ocrelizumab similar biotherapeutic product","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOOUt1VFR4WDN1Y29TQ0RlbUpYTE05RWxVWFRETkFKSDYtLVZjTENBcm1TOEllTFdVQkVnV25CZ0VKN0pmLWFHWndDb2NQTURFdEswQThYdjdrcWEyb3p2UnVUNU9wZlJ3N0tfdXBrbnFtU3R2LTJaLVhrQlpUdVJNQWpLLUVXMENXVHpSWDdNR1V5blZfRmdUVzBqcXdMbEo2SGRtc3pNbFYtRmc?oc=5","date":"2021-07-02","type":"patent","source":"Generics and Biosimilars Initiative","summary":"MENA region biologicals maker CinnaGen receives EU GMP certification - Generics and Biosimilars Initiative","headline":"MENA region biologicals maker CinnaGen receives EU GMP certification","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOWEtSQWlSM2NWZFlvRkpIbVdnMng5YWNRSzRxRFh1ZjBjTVRsVFRXbFJfM3R6YWc0TUxrRUIwX2xjLVVZbWRjQ18wY3lTTC05aVowY245RFpHdi1neDNiSV9KQWxyWFNQbHZicThzSlVCX0dZTEcteFpIWGt4cHFNNEhUSUtQWDFEUUxncWVMNmRpVTFISXEweQ?oc=5","date":"2021-07-02","type":"regulatory","source":"Generics and Biosimilars Initiative","summary":"MENA mAb manufacturer AryoGen receives EU GMP approval - Generics and Biosimilars Initiative","headline":"MENA mAb manufacturer AryoGen receives EU GMP approval","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxOUzNtMVVGNFFFd0wyQTkxSGVVX09HbzBJejJYcElXdEhlTnYwalVvLUdvY0tBc0E4SExsUzF1VzgxOTRCOFFPQ1JMVUhmekM2UUV1U3JNYjA5c0lNdUV1aE1nRkdORlc3OVZYVHVXaXlkMnJ3c1VjVkNZa1M0XzJ4QVBiTlBnbW5ja2c?oc=5","date":"2019-12-16","type":"pipeline","source":"ArchDaily","summary":"CinnaGen Pharmaceutical Company / Modaam Architects - ArchDaily","headline":"CinnaGen Pharmaceutical Company / Modaam Architects","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxQOFRXOHF0bVFhdlk0M1loYld5d1E3YXZTUG5LSlNGQWgwX1hqbjRBdXdqMjgyU1NiajBpMmdlQUt5Y29aSmNDSF9UUlJGTFl5eHljT29mTjNqQml1VWlrRFhUeWdDZUp4bWpGYlpoR0x1M2JfRDZfbDBYS2llQW8xS24tYjdQbUFfYVFnSXJIblRLVjZQLUI3aTJ2RERJZE5EQ1JxVDd6V3hXQ2FWNG1HNDhJNXZpWW4yZk1SdWExU25Kc3lWX1hlVk1GVktHd1Vwc2FJM1BTeVYtNXBCV3ByWGU2M1J0alNKLVFSVGNieThlSEFldXc?oc=5","date":"2019-12-16","type":"pipeline","source":"ArchDaily","summary":"Gallery of CinnaGen Pharmaceutical Company / Modaam Architects - 4 - ArchDaily","headline":"Gallery of CinnaGen Pharmaceutical Company / Modaam Architects - 4","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOb2xITTlfdTRzYXVJcENLS0JjQ1NXcGx1S0JtRzVlTFdWM3ZCTWc3U0RZaVJTelJqTVMtZDhIcnJwWVlzTnFHb3lxSW5YcEZ3ak9WQnhZVFlkeUZfSG9RY1RvejZYV3hTeVFOT2JndjZvYzJBWk80WDNsbVBXUWF4YnNZNmxpZXN4Xzg0b0VvV1FsUlNLTUMyZHlIVExWaG1ULXRtTU8tOGNSVlItbFA5a2V3?oc=5","date":"2019-06-13","type":"patent","source":"Fierce Pharma","summary":"Iranian drugmaker opens $100M plant in Turkey, will make Humira biosimilar - Fierce Pharma","headline":"Iranian drugmaker opens $100M plant in Turkey, will make Humira biosimilar","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2019-06-13","type":"pipeline","source":"Daily Sabah","summary":"Global medicine giant CinnaGen opens $100M biotech plant in Çerkezköy | Daily Sabah - Daily Sabah","headline":"Global medicine giant CinnaGen opens $100M biotech plant in Çerkezköy | Daily Sabah","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQR1NOVjJZRk1jMWhOY0FKRDVJZ3NJZTZZNVl5UWRndk9qOWRCQ0FDZGxSdEtNTUR6VjRrSXl0SVhWZG5vLVk3OGNLT0pUNXhZQzRqVElRM2RBQTZHbjZMY2VPLWpQX3JXa1VSMHg0NFVqdWo2UVQzRDNDZ0d1RWJEbzd2V2JheGtLa3pNeWVMRFhQWkh5V204WlVvemljNVBsbUs4?oc=5","date":"2017-03-10","type":"patent","source":"Generics and Biosimilars Initiative","summary":"CinnaGen to invest in Turkish pharmaceuticals sector - Generics and Biosimilars Initiative","headline":"CinnaGen to invest in Turkish pharmaceuticals sector","sentiment":"neutral"}],"patents":[],"drugCount":11,"phaseCounts":{"phase_3":11},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}